Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Interventional × molibresib × Clear all
NCT01943851 2024-10-01

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

GlaxoSmithKline

Phase 2 Completed
111 enrolled 71 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡